We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+25.16%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.46B
AUM Growth
+$147M
Cap. Flow
-$82.7M
Cap. Flow %
-5.66%
Top 10 Hldgs %
25.13%
Holding
215
New
28
Increased
57
Reduced
41
Closed
25

Top Buys

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$31.1M
2
MRK icon
Merck
MRK
+$27.8M
3
MIRM icon
Mirum Pharmaceuticals
MIRM
+$24.3M
4
IMGN
Immunogen Inc
IMGN
+$14.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$14.1M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$29.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$28.4M
3
UTHR icon
United Therapeutics
UTHR
+$26.8M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$25.8M
5
PODD icon
Insulet
PODD
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 53.92%
2 Technology 13.34%
3 Industrials 8.74%
4 Consumer Discretionary 4.85%
5 Energy 4.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LSCC icon
26
Lattice Semiconductor
LSCC
$18.5B
$18.6M 1.27%
193,348
-16,088
-8% -$1.38M
XOM icon
27
ExxonMobil
XOM
$634B
$17.5M 1.2%
163,000
– –
CACI icon
28
CACI
CACI
$14.2B
$17.3M 1.18%
50,791
+981
+2% +$305K
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$29.3B
$17.2M 1.17%
90,351
– –
CELH icon
30
Celsius Holdings
CELH
$7.1B
$16.5M 1.13%
331,938
-44,061
-12% -$1.75M
IRDM icon
31
Iridium Communications
IRDM
$5.29B
$16.1M 1.1%
259,622
+44,968
+21% +$2.78M
CHX
32
DELISTED
ChampionX
CHX
$15.7M 1.07%
505,756
+16,676
+3% +$459K
ASND icon
33
Ascendis Pharma A/S
ASND
$16.8B
$15.2M 1.04%
170,609
-80,778
-32% -$7.03M
TFII icon
34
TFI International
TFII
$11.5B
$14.9M 1.02%
130,996
-25,497
-16% -$2.8M
FLNC icon
35
Fluence Energy
FLNC
$2.44B
$14.1M 0.97%
530,662
+475,301
+859% +$10.6M
SYM icon
36
Symbotic
SYM
$5.22B
$13.9M 0.95%
325,321
-80,248
-20% -$2.64M
MSFT icon
37
Microsoft
MSFT
$3.71T
$12.8M 0.88%
37,694
+8,594
+30% +$2.69M
ISEE
38
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$12.8M 0.88%
+325,548
New +$11.5M
CVX icon
39
Chevron
CVX
$366B
$12.8M 0.88%
81,350
– –
AVGO icon
40
Broadcom
AVGO
$2.04T
$11M 0.75%
126,510
– –
TMHC
41
DELISTED
Taylor Morrison
TMHC
$10.7M 0.73%
219,637
+564
+0.3% +$24.3K
NVDA icon
42
NVIDIA
NVDA
$5.42T
$10.4M 0.71%
246,820
-850
-0.3% -$28.2K
BHVN icon
43
Biohaven
BHVN
$2.21B
$10.2M 0.7%
425,000
-475,270
-53% -$8.18M
ARCB icon
44
ArcBest
ARCB
$3.08B
$9.44M 0.65%
95,555
+448
+0.5% +$40K
ARES icon
45
Ares Management
ARES
$30.9B
$9.26M 0.63%
96,105
– –
MTG icon
46
MGIC Investment
MTG
$6.25B
$8.97M 0.61%
568,202
+316,684
+126% +$4.7M
SMCI icon
47
Super Micro Computer
SMCI
$20.1B
$8.13M 0.56%
+326,340
New +$5.47M
EVR icon
48
Evercore
EVR
$11.8B
$8M 0.55%
64,691
+21,266
+49% +$2.45M
WING icon
49
Wingstop
WING
$3.18B
$7.94M 0.54%
39,649
-16,950
-30% -$3.31M
CBAY
50
DELISTED
Cymabay Therapeutics
CBAY
$7.63M 0.52%
+696,947
New +$6.49M
1
2
3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Nicholas Investment Partners held 215 positions worth $1.46B, up 11% from $1.32B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Nicholas Investment Partners withdrew a net $82.7M in Q2 2023, closing 25 positions and reducing 41 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $29.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 53% a quarter earlier, followed by Technology and Industrials.

Against the trend, Nicholas Investment Partners opened a new position in Intra-Cellular Therapies Inc. worth $31.6M.

  • Nicholas Investment Partners's largest Q2 2023 buy was Intra-Cellular Therapies Inc.: 499,503 shares worth $31.6M.
  • Nicholas Investment Partners added most to Xenon Pharmaceuticals in Q2 2023, an estimated $14.1M increase.
  • Nicholas Investment Partners's biggest Q2 2023 reduction was Lantheus, cutting an estimated $9.72M.
  • Nicholas Investment Partners fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $29.3M.
  • Nicholas Investment Partners's ten largest holdings make up 25% of its $1.46B portfolio in Q2 2023.
  • Nicholas Investment Partners opened 28 new positions and closed 25 in Q2 2023.
  • Nicholas Investment Partners's portfolio value rose 11% quarter-over-quarter to $1.46B.

Based on Nicholas Investment Partners's 13F filing for Q2 2023, filed 10 Aug 2023.